尼罗丁尼诱导的内皮细胞功能的改变重现了独立于ABL1的临床血管表型
Emily A Pinheiro1,2, Jean-Marc DeKeyser1,2, Brian Lenny3
1Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Scientific reports
|March 27, 2024
概括
尼罗丁尼通过损害内皮细胞引起动脉疾病,而不是通过其主要点ABL1.1,从而引起动脉疾病. 这一发现为了解和预防尼洛丁尼诱导的动脉疾病提供了新的途径.
科学领域:
- 心血管生物学 心血管生物学
- 血液瘤学 血液瘤学
- 干细胞生物学 干细胞生物学
背景情况:
- 尼罗丁尼是慢性髓性白血病的关键治疗方法.
- 尼罗丁尼诱导的动脉疾病 (NAD) 是一种已知的副作用,但其机制和介导细胞类型尚不清楚.
- 了解NAD的起源对于患者安全和治疗优化至关重要.
研究的目的:
- 研究尼洛尼布诱导的动脉疾病 (NAD) 背后的细胞机制.
- 为了确定NAD是否来自ABL1的目标抑制或非目标效应.
- 建立一个体外模型来研究使用患者衍生细胞的NAD.
主要方法:
- 从诱导多能干细胞 (hiPSCs) 中生成人类内皮细胞和血管光滑肌细胞.
- 在体外评估尼罗丁尼对内皮细胞增殖,迁移,屏障功能和氧化水平的影响.
- 评估尼洛尼在ABL1淘汰细胞系中的影响,以区分在标和非标效应.
主要成果:
- 尼罗丁尼抑制了内皮细胞的增殖和迁移,并增加了细胞内氧化.
- 内皮屏障功能和脂质吸收不受尼洛尼的影响.
- 尼罗丁尼对血管光滑肌细胞没有不良影响,这表明内皮细胞是NAD的主要媒介.
- 尼洛尼的有害作用在ABL1淘汰细胞中持续存在,这表明非目标机制.
结论:
- 尼罗丁尼诱导的动脉疾病主要由内皮细胞功能障碍介导.
- NAD似乎是来自非目标信号通路的结果,而不是对ABL1.1的增强抑制.
- 开发的基于hiPSC的模型为未来的NAD机制学和药物基因组学研究提供了一个平台.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K


